Tempus AI, Inc. (NASDAQ:TEM – Get Free Report)’s stock price crossed below its 200-day moving average during trading on Friday after an insider sold shares in the company. The stock has a 200-day moving average of $57.55 and traded as low as $53.26. Tempus AI shares last traded at $53.9760, with a volume of 7,412,144 shares traded.
Specifically, CAO Ryan Bartolucci sold 1,540 shares of the company’s stock in a transaction that occurred on Tuesday, November 17th. The stock was sold at an average price of $63.02, for a total value of $97,050.80. Following the completion of the sale, the chief accounting officer owned 59,264 shares of the company’s stock, valued at $3,734,817.28. This represents a 2.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CEO Ryan Fukushima sold 10,247 shares of Tempus AI stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $63.02, for a total value of $645,765.94. Following the completion of the sale, the chief executive officer directly owned 652,216 shares of the company’s stock, valued at $41,102,652.32. The trade was a 1.55% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In related news, CFO James Rogers sold 7,079 shares of the business’s stock in a transaction on Tuesday, November 17th. The stock was sold at an average price of $63.02, for a total transaction of $446,118.58. Following the completion of the transaction, the chief financial officer owned 98,945 shares in the company, valued at $6,235,513.90. The trade was a 6.68% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Wall Street Analysts Forecast Growth
TEM has been the subject of a number of recent analyst reports. Piper Sandler upgraded Tempus AI from a “neutral” rating to an “overweight” rating and boosted their price objective for the company from $56.00 to $76.00 in a research report on Tuesday, September 1st. Jefferies Financial Group raised Tempus AI from an “underperform” rating to a “hold” rating and raised their price objective for the stock from $35.00 to $70.00 in a report on Tuesday, November 3rd. Wall Street Zen raised shares of Tempus AI from a “sell” rating to a “hold” rating in a report on Saturday, July 25th. HC Wainwright reissued a “buy” rating and set a $85.00 target price on shares of Tempus AI in a research report on Thursday. Finally, Robert W. Baird raised their price target on Tempus AI from $85.00 to $92.00 and gave the stock an “outperform” rating in a report on Tuesday, November 3rd. Eleven equities research analysts have rated the stock with a Buy rating, ten have assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $79.37.
Key Headlines Impacting Tempus AI
Here are a few of the latest headlines about TEM:
- Positive Sentiment: Tempus plans to present 16 abstracts at the 2026 San Antonio Breast Cancer Symposium, which could increase visibility for its research and precision-medicine platform. Tempus to present 16 abstracts
- Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $85 price target, indicating confidence in Tempus’s outlook. HC Wainwright rating
- Neutral Sentiment: Several senior executives, including the CEO and CFO, sold shares. The filings say the sales covered tax withholding obligations on vested equity awards, making them less indicative of a change in confidence, though multiple insider sales may still draw investor attention. Insider sale report
Tempus AI Stock Down 9.5%
The stock has a market capitalization of $9.85 billion, a P/E ratio of -50.92 and a beta of 3.61. The stock’s fifty day simple moving average is $72.79 and its two-hundred day simple moving average is $57.55. The company has a debt-to-equity ratio of 2.70, a quick ratio of 2.48 and a current ratio of 2.61.
Tempus AI (NASDAQ:TEM – Get Free Report) last issued its earnings results on Monday, November 2nd. The company reported $0.07 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.16. Tempus AI had a negative return on equity of 47.00% and a negative net margin of 12.54%. The business had revenue of $411.54 million during the quarter, compared to the consensus estimate of $409.39 million. During the same quarter last year, the company earned ($0.46) EPS. The firm’s revenue was up 23.1% compared to the same quarter last year. As a group, research analysts expect that Tempus AI, Inc. will post -1.20 EPS for the current fiscal year.
Hedge Funds Weigh In On Tempus AI
A number of large investors have recently added to or reduced their stakes in TEM. PCM Encore LLC purchased a new stake in Tempus AI during the 3rd quarter worth approximately $201,000. Advisors Asset Management Inc. acquired a new position in shares of Tempus AI in the 3rd quarter valued at approximately $3,977,000. Integrated Wealth Concepts LLC boosted its holdings in shares of Tempus AI by 44.3% during the third quarter. Integrated Wealth Concepts LLC now owns 3,618 shares of the company’s stock valued at $296,000 after acquiring an additional 1,110 shares during the period. Schwarz Investment Partners Inc. purchased a new position in Tempus AI in the 3rd quarter worth about $109,000. Finally, New York State Common Retirement Fund lifted its position in shares of Tempus AI by 3.0% during the third quarter. New York State Common Retirement Fund now owns 54,400 shares of the company’s stock worth $4,455,000 after purchasing an additional 1,600 shares in the last quarter. 24.22% of the stock is currently owned by institutional investors and hedge funds.
Tempus AI Company Profile
Tempus AI is a technology company focused on applying data and artificial intelligence to healthcare, with an emphasis on precision medicine. Its platform combines clinical and molecular data to help physicians make more informed treatment decisions and support life-sciences research. The company provides genomic sequencing and other diagnostic testing, software tools for analyzing patient data, and services that help identify clinical trial opportunities. Its work spans oncology and other areas of medicine, and it collaborates with healthcare providers and pharmaceutical and biotechnology companies.
Featured Articles
- Five stocks we like better than Tempus AI
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
